Tolerability of two sequential electroporation treatments using MedPulser DNA delivery system (DDS) in healthy adults

Molecular Therapy

Volumn 17, Issue 5, 2009, Pages 922-928

  Wallace, Mark ^a   Evans, Barbara ^b   Woods, Sandra ^a   Mogg, Robin ^b   Zhang, Lei ^c   Finnefrock, Adam C ^b   Rabussay, Dietmar ^c   Fons, Michael ^c   Mallee, John ^b   Mehrotra, Devan ^b   Schödel, Florian ^b   Musey, Luwy ^b  

^a University of California   (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

^c Inovio Biomedical Corporation   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN; DNA;

ADULT; ARTICLE; BLEEDING; DEVICE; ELECTROPORATION; ERYTHEMA; FEMALE; GENE DELIVERY SYSTEM; HEADACHE; HUMAN; IMMUNE RESPONSE; INFECTION; INFESTATION; INJECTION SITE REACTION; MALE; NEUROLOGIC DISEASE; PAIN; PAIN ASSESSMENT; QUESTIONNAIRE; RATING SCALE; SCORING SYSTEM; SWELLING; SYNCOPE; TIME; TOOTH INFECTION;

ADOLESCENT; ADULT; ELECTROPORATION; FEMALE; GENE THERAPY; HUMANS; IMMUNOTHERAPY; MALE; PAIN MEASUREMENT; YOUNG ADULT;

EID: 67349242763     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2009.27     Document Type: Article

References (37)

1. Arvin, AM and Greenberg, HB (2006). New viral vaccines. Virology 344: 240-249.
2. Grijalva, CG and Griffin, MR (2008). Population-based impact of routine infant immunization with pneumococcal conjugate vaccine in the USA. Expert Rev Vaccines 7: 83-95.
3. Lowe, DB, Shearer, MH and Kennedy, RC (2006). DNA vaccines: Successes and limitations in cancer and infectious disease. J Cell Biochem 98: 235-242.
4. Chestnut, RW, Sette, A, Celis, E, Wentworth, P, Kubo, RT, Alexander, J et al. (1995). Design and testing of peptide-based cytotoxic T-cell-mediated immunotherapeutics to treat infectious diseases and cancer. In: Powell MF, Newman MJ (eds). Vaccine Design: The Subunit and Adjuvant Approach. Plenum Press: New York, pp. 847-874.
5. Facciabene, A, Aurisicchio, L, Elia, L, Palombo, F, Mennuni, C, Ciliberto, G et al. (2006). DNA and adenoviral vectors encoding carcinoembryonic antigen fused to immunoenhancing sequences augment antigen-specific immune response and confer tumor protection. Hum Gene Ther 17: 81-92.
6. Ugen, KE, Kutzler, MA, Marrero, B, Westover, J, Coppola, D, Weiner, DB et al. (2006). Regression of subcutaneous B16 melanoma tumors after intratumoral delivery of an IL-15-expressing plasmid followed by in vivo electroporation. Cancer Gene Ther 13: 969-974.
7. Hirao, LA, Wu, L, Khan, AS, Hokey, DA, Yan, J, Dai, A et al. (2008). Combined effects of IL-12 and electroporation enhances the potency of DNA vaccination in macaques. Vaccine 26: 3112-3120.
8. Dupuis, M, Denis-Mize, K, Woo, C, Goldbeck, C, Selby, MJ, Chen, M et al. (2000). Distribution of DNA vaccines determines their immunogenicity after intramuscular injection in mice. J Immunol 165: 2850-2858.
9. Ulmer, JB, Wahren, B and Liu, MA (2006). Gene-based vaccines: Recent technical and clinical advances. Trends Mol Med 12: 216-222.
10. Neumann, E, Kakorin, S and Toensing, K (1999). Fundamentals of electroporative delivery of drugs and genes. Bioelectrochem Bioenerg 48: 3-16.
11. Zhang, L, Widera, G and Rabussay, D (2004). Enhancement of the effectiveness of electroporation-augmented cutaneous DNA vaccination by particulate adjuvant. Bioelectrochemistry 63: 369-373.
12. Ahlén, G, Soderhölm, J, Tjelle, T, Kjeken, R, Frelin, L, Höglund, U et al. (2007). In vivo electroporation enhances the immunogenicity of hepatitis C virus nonstructural 3/4A DNA by increased local DNA uptake, protein expression, inflammation, and infiltration of CD3+ T cells. J Immunol 179: 4741-4753.
13. Chiarella, P, Massi, E, De Robertis, M, Sibilio, A, Parrella, P, Fazio, VM et al. (2008). Electroporation of skeletal muscle induces danger and signal release and antigen-presenting cell recruitment independently of DNA vaccine administration. Expert Opin Biol Ther 8: 1645-1657.
14. Otten, G, Schaefer, M, Doe, B, Liu, H, Srivastava, I, zur Megede, J et al. (2004). Enhancement of DNA vaccine potency in rhesus macaques by electroporation. Vaccine 22: 2489-2493.
15. Widera, G, Austin, M, Rabussay, D, Goldbeck, C, Barnett, SW, Chen, M et al. (2000). Increased DNA vaccine delivery and immunogenicity by electroporation in vivo. J Immunol 164: 4635-4640.
16. Zucchelli, S, Capone, S, Fattori, E, Folgori, A, Di Marco, A, Casimiro, D et al. (2000). Enhancing B- and T-cell immune response to a Hepatitis C virus E2 DNA vaccine by intramuscular electrical gene transfer. J Virol 74: 11598-11607.
17. Simon, A, Casimiro, DR, Finnefrock, AC, Davies, ME, Tang, A, Chen, M et al. (2008). Enhanced in vivo transgene expression and immunogenicity from plasmid vectors following electrostimulation in rodents and primates. Vaccine 26: 5202-5209.
18. Babiuk, S, Baca-Estrada, ME, Foldvari, M, Storms, M, Rabussay, D, Widera, G et al. (2002). Electroporation improves the efficacy of DNA vaccines in large animals. Vaccine 20: 3399-3408.
19. LeBlanc, R, Vasquez, Y, Hannaman, D and Kumar, N (2008). Markedly enhanced immunogenicity of a Pfs25 DNA-based malaria transmission-blocking vaccine by in vivo electroporation. Vaccine 26: 185-192.
20. van Drunen Little-van den Hurk, S, Luxembourg, A, Ellefsen, B, Wilson, D, Ubach, A, Hannaman et al. (2008). Electroporation-based DNA transfer enhances gene expression and immune responses to DNA vaccines in cattle. Vaccine 26: 5503-5509.
21. Glass, LF, Pepine, ML, Fenske, NA, Jaroszeski, M, Reintgen, DS and Heller, R (1996). Bleomycin-mediated electrochemotherapy of metastatic melanoma. Arch Dermatol 132: 1353-1357.
22. Rabussay, D (2008). Applicator and electrode design for in vivo DNA delivery by electroporation. Methods Mol Biol 423: 35-59.
23. Zhang, L, Finnefrock, AC, Casimiro, DR and Rabussay, D (2008). DNA vaccination using the MedPulser DNA Delivery System in rhesus macaques: Development of clinical electroporation parameters. 11th Annual Meeting of the ASGT, Boston, MA. Abstract #396.
24. Melzack, R (1987). The short-form McGill pain questionnaire. Pain 30: 191-197.
25. Cleeland, CS and Ryan, KM (1994). Pain assessment: Global use of the Brief Pain Inventory. Ann Acad Med Singapore 23: 129-138.
26. Coplan, PM, Schmader, K, Nikas, A, Chan, IS, Choo, P, Levin, MJ et al. (2004). Development of a measure of the burden of pain due to herpes zoster and postherpetic neuralgia for prevention trials: adaptation of the brief pain inventory. J Pain 5: 344-356.
27. Zelman, DC, Dukes, E, Brandenburg, N, Bostrom, A and Gore, M (2005). Identification of cut-points for mild, moderate and severe pain due to diabetic peripheral neuropathy. Pain 115: 29-36.
28. Nemeth, KA, Graham, ID and Harrisson, MB (2003). The measurement of leg ulcer pain: Identification and appraisal of pain assessment tools. Adv Skin Wound Care 16: 260-267.
29. Hwang, SS, Chang, VT and Kasimis, B (2002). Dynamic cancer pain management outcomes: The relationship between pain severity, pain relief, functional interference, satisfaction and global quality of life over time. J Pain Symptom Manage 23: 190-200.
30. Fuller, DH, Loudon, P and Schmaljohn, C (2006). Preclinical and clinical progress of particle-mediated DNA vaccines for infectious diseases. Methods 40: 86-97.
31. Orlowski, S, Belehrader, J Jr, Paoletti, C and Mir, LM (1988). Transient electropermeabilization of cells in culture. Increase of the cytotoxicity of anticancer drugs. Biochem Pharmacol 37: 4727-4733.
32. Rabussay, DP, Nanda, GS and Goldfarb, PM (2002). Enhancing the effectiveness of drug-based cancer therapy by electroporation (electropermeabilization). Technol Cancer Res Treat 1: 71-82.
33. Gothelf, A, Mir, LM and Gehl, J (2003). Electrochemotherapy: Results of cancer treatment using enhanced delivery of bleomycin by electroporation. Cancer Treat Rev 29: 371-387.
34. Luxembourg, A, Evans, CF and Hannaman, D (2007). Electroporation-based DNA immunization: Translation to the clinic. Expert Opin Biol Ther 7: 1647-1664.
35. Harper, DM, Franco, EL, Wheeler, C, Ferris, DG, Jenkins, D, Schuind, A et al. (2004). Efficacy of bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: A randomized controlled trial. Lancet 364: 1757-1765.
36. Halperin, SA, Langley, JM, Smith, B, Wunderli, P, Kaufman, L, Kimura, A et al. (2007). Phase I first-in-human studies of the reactogenicity and immunogenicity of a recombinant meningococcal NspA vaccine in healthy adults. Vaccine 25: 450-457.
37. McNeil, SA, Noya, F, Dionne, M, Predy, G, Meekison, W, Ojah, C et al. (2007). Comparison of the safety and immunogenicity of an adult formulation tetanus and diphtheria toxoids adsorbed combined with acellular pertussis (Tdap) vaccine and trivalent inactivated influenza vaccine in adults. Vaccine 25: 3464-3474.